July 27, 2022
Article
Oncology Live®
During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.
July 27, 2022
Article
The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
July 26, 2022
Article
A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.
July 25, 2022
Article
Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.
July 18, 2022
Article
Peer-reviewed articles continue to challenge the recognition of progression-free survival as an acceptable primary end point in randomized cancer trials or insist on labeling this objectively measured outcome as nothing more than a potential surrogate for effects representing actual clinically meaningful results.